Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

630 - The phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for head and neck cancer patients

Date

10 Sep 2017

Session

Poster display session

Presenters

Tomoya Yokota

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

T. Yokota1, S. Hamauchi1, Y. Yoshida1, T. Yurikusa2, M. Suzuki2, A. Yamashita3, H. Ogawa4, T. Onoe4, K. Mori5, T. Onitsuka6

Author affiliations

  • 1 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2 Division Of Dental And Oral Surgery, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 3 Division Of Nutrition, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 4 Division Of Radiation Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 5 Clinical Trial Coordination Office, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 6 Divisions Of Head And Neck Surgery, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
More

Resources

Abstract 630

Background

Opioid-based pain control and systemic oral care program are effective for the chemoradiotherapy (CRT)-induced severe oral mucositis (OM) in patients with head and neck cancers (HNC). This phase II trial assessed the clinical benefit of beta-Hydroxy-beta-Methylbutyrate, Arginine, and Glutamine (HMB/Arg/Gln) in the prevention of CRT-induced OM in patients with HNC.

Methods

Patients with HNC who were scheduled to receive definitive or postoperative cisplatin-based CRT were enrolled. HMB/Arg/Gln was administered orally or per percutaneous endoscopic gastrostomy from the first day of CRT up to completion of CRT. All patients received opioid-based pain control and oral care programs we previously published. The primary endpoint was the incidence of grade ≥3 OM (functional/symptomatic) according to the Common Terminology Criteria of Adverse Events version 3.0. QOL (EORTC QLQ-C30/PROMS) and intake of nutrition at baseline and 50Gy were also assessed.

Results

From February 2015 to June 2016, 35 patients with HNC were enrolled. Sixteen patients (45.7%) developed grade ≥3 OM (i.e., functional/symptomatic). The incidence of grade ≤1 OM (functional/symptomatic) was 51.5% at 2 weeks and 82.9% at 4 weeks after completion of RT. Clinical examination revealed that 10 patients (28.6%) developed grade ≥3 OM. The incidence of grade ≤1 OM (clinical exam) was 80.0% at 2 weeks and 100% at 4 weeks after completion of RT. Only 5.7% of patients had unplanned breaks in radiotherapy, and all patients completed treatment. Adverse events related to HMB/Arg/Gln were increase in blood urea nitrogen and diarrhea, but were easily managed.

Conclusions

Addition of HMB/Arg/Gln to opioid-based pain control and oral care programs was feasible but still insufficient in reducing the incidence of severe CRT-induced oral mucositis. However, the benefit of HMB/Arg/Gln should not be neglected in terms of findings of clinical examination and the recovery from severe oral mucositis.

Clinical trial identification

UMIN000016453

Legal entity responsible for the study

None

Funding

Public Interest Incorporated Foundation- Shizuoka Industrial Foundation- Pharma Valley Center

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.